Literature DB >> 17661704

Extended-spectrum cephalosporinases: structure, detection and epidemiology.

Patrice Nordmann1, Hedi Mammeri.   

Abstract

Extended-spectrum AmpC beta-lactamases of Enterobacteriaceae, which are chromosomally or plasmid-encoded, possess structural modifications in the vicinity of the active site compared with their progenitors. They display an increased catalytic efficiency against extended-spectrum beta-lactams, such as ceftazidime, cefotaxime, cefepime, cefpirome and, in some cases, also against imipenem. An overview of the molecular and biochemical characterization of this recently identified mechanism of resistance to beta-lactams is provided as well as its prevalence and possible clinical significance.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17661704     DOI： 10.2217/17460913.2.3.297

Source DB:  PubMed          Journal:  Future Microbiol        ISSN： 1746-0913            Impact factor:   3.165


  37 in total

1.  Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase.

Authors:  Stathis D Kotsakis; Costas C Papagiannitsis; Eva Tzelepi; Leonidas S Tzouvelekis; Vivi Miriagou
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191

Review 2.  Clinical and laboratory considerations for the rapid detection of carbapenem-resistant Enterobacteriaceae.

Authors:  Ritu Banerjee; Romney Humphries
Journal:  Virulence       Date:  2016-05-11       Impact factor: 5.882

3.  Occurrence of ST23 complex phylogroup A Escherichia coli isolates producing extended-spectrum AmpC beta-lactamase in a French hospital.

Authors:  Lise Crémet; Nathalie Caroff; Cécile Giraudeau; Sandie Dauvergne; Didier Lepelletier; Alain Reynaud; Stéphane Corvec
Journal:  Antimicrob Agents Chemother       Date:  2010-02-09       Impact factor: 5.191

Review 4.  Updated functional classification of beta-lactamases.

Authors:  Karen Bush; George A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

5.  Activity of temocillin, mecillinam, ceftazidime, and ceftazidime/avibactam against carbapenem-non-susceptible Enterobacteriaceae without carbapenemase production.

Authors:  N T Mutters; S Zimmermann; M Kaase; A Mischnik
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-10-03       Impact factor: 3.267

6.  Increased Hydrolysis of Oximino-β-Lactams by CMY-107, a Tyr199Cys Mutant Form of CMY-2 Produced by Escherichia coli.

Authors:  S D Kotsakis; V Miriagou; E E Vetouli; E Bozavoutoglou; E Lebessi; E Tzelepi; L S Tzouvelekis
Journal:  Antimicrob Agents Chemother       Date:  2015-10-05       Impact factor: 5.191

7.  Emergence of ertapenem resistance in an Escherichia coli clinical isolate producing extended-spectrum beta-lactamase AmpC.

Authors:  Hélène Guillon; Didier Tande; Hedi Mammeri
Journal:  Antimicrob Agents Chemother       Date:  2011-07-11       Impact factor: 5.191

8.  Identification of genotypes of plasmid-encoded AmpC beta-lactamases from clinical isolates and characterization of mutations in their promoter and attenuator regions.

Authors:  Gui-Ling Li; Li-Bo Duo; Ying Luan; Cheng-Ying Wang; Wei-Ping Wang; He-Guang Zhang; Qi Sun; Gui-Yun Qi
Journal:  Gene Expr       Date:  2012

Review 9.  The use of cephalosporins for gonorrhea: the impending problem of resistance.

Authors:  Pennan M Barry; Jeffrey D Klausner
Journal:  Expert Opin Pharmacother       Date:  2009-03       Impact factor: 3.889

10.  Characterization of the new AmpC β-lactamase FOX-8 reveals a single mutation, Phe313Leu, located in the R2 loop that affects ceftazidime hydrolysis.

Authors:  Francisco José Pérez-Llarena; Frédéric Kerff; Laura Zamorano; María Carmen Fernández; Maria Luz Nuñez; Elisenda Miró; Antonio Oliver; Ferran Navarro; Germán Bou
Journal:  Antimicrob Agents Chemother       Date:  2013-07-22       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.